Aether Industries Ltd
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol.[1]
- Market Cap ₹ 11,913 Cr.
- Current Price ₹ 898
- High / Low ₹ 1,071 / 762
- Stock P/E 117
- Book Value ₹ 161
- Dividend Yield 0.00 %
- ROCE 7.82 %
- ROE 5.93 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.2% over last 3 years.
- Working capital days have increased from 297 days to 440 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE 500 BSE Commodities Nifty Microcap 250 BSE 250 SmallCap Index BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 0 | 24 | 109 | 201 | 302 | 450 | 590 | 651 | 596 | 647 | |
1 | 3 | 1 | 22 | 85 | 154 | 230 | 338 | 422 | 465 | 464 | 508 | |
Operating Profit | -1 | -2 | -1 | 2 | 23 | 48 | 72 | 112 | 168 | 186 | 131 | 139 |
OPM % | -252% | -194% | 10% | 21% | 24% | 24% | 25% | 28% | 29% | 22% | 21% | |
3 | 4 | 1 | 0 | 0 | 2 | 2 | 4 | 7 | 17 | 30 | 31 | |
Interest | 1 | 1 | 0 | 1 | 9 | 11 | 9 | 11 | 13 | 5 | 9 | 10 |
Depreciation | 0 | 0 | 0 | 1 | 5 | 6 | 8 | 11 | 15 | 23 | 39 | 41 |
Profit before tax | 0 | 0 | 0 | 1 | 9 | 33 | 57 | 94 | 146 | 174 | 114 | 119 |
Tax % | 39% | 27% | 31% | 300% | 17% | 28% | 29% | 24% | 26% | 25% | 23% | |
0 | 0 | 0 | -1 | 8 | 23 | 40 | 71 | 109 | 130 | 88 | 88 | |
EPS in Rs | 0.14 | 0.12 | 0.11 | -1.27 | 9.08 | 27.27 | 46.68 | 70.43 | 9.67 | 10.47 | 6.65 | 6.67 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 10% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 50% |
5 Years: | 33% |
3 Years: | 11% |
TTM: | -28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 15% |
3 Years: | 12% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 34 | 9 | 9 | 9 | 9 | 10 | 113 | 125 | 133 | 133 |
Reserves | 0 | 0 | 0 | -1 | 7 | 30 | 70 | 164 | 274 | 1,120 | 1,936 | 2,006 |
40 | 35 | 53 | 111 | 126 | 126 | 172 | 211 | 291 | 16 | 144 | 157 | |
1 | 1 | -21 | 19 | 18 | 42 | 50 | 67 | 92 | 120 | 143 | 214 | |
Total Liabilities | 50 | 45 | 65 | 137 | 159 | 207 | 300 | 453 | 770 | 1,380 | 2,356 | 2,510 |
2 | 1 | 1 | 56 | 100 | 106 | 129 | 216 | 257 | 646 | 743 | 757 | |
CWIP | 7 | 20 | 42 | 40 | 2 | 1 | 17 | 0 | 58 | 37 | 219 | 322 |
Investments | 16 | 8 | 0 | 0 | 0 | 0 | 0 | 22 | 17 | 1 | 0 | 100 |
25 | 15 | 21 | 41 | 56 | 99 | 154 | 214 | 438 | 695 | 1,393 | 1,330 | |
Total Assets | 50 | 45 | 65 | 137 | 159 | 207 | 300 | 453 | 770 | 1,380 | 2,356 | 2,510 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
-1 | -3 | -6 | -9 | 6 | 23 | 18 | 23 | -5 | -7 | -2 | |
-33 | 2 | -14 | -48 | -11 | -13 | -48 | -77 | -151 | -348 | -399 | |
47 | -6 | 17 | 57 | 4 | -10 | 33 | 55 | 169 | 439 | 854 | |
Net Cash Flow | 13 | -8 | -3 | -1 | -0 | 0 | 2 | 2 | 12 | 84 | 453 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94 | 4,358 | 167 | 88 | 87 | 76 | 88 | 101 | 145 | 141 | |
Inventory Days | 52 | 9,733 | 629 | 149 | 133 | 166 | 141 | 221 | 301 | 411 | |
Days Payable | 172 | 1,922 | 575 | 92 | 76 | 88 | 82 | 95 | 99 | 113 | |
Cash Conversion Cycle | -25 | 12,169 | 220 | 144 | 144 | 153 | 147 | 227 | 348 | 439 | |
Working Capital Days | 3,568 | 15,983 | 304 | 123 | 71 | 97 | 121 | 183 | 269 | 440 | |
ROCE % | -1% | -0% | 2% | 14% | 28% | 32% | 33% | 30% | 18% | 8% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10h - Outcome of investor meeting with White Oak Capital.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13h - Outcome of investor meeting in Hong Kong.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Outcome of investor meeting in Singapore.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Outcome of investor meeting in Singapore.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Dec - In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, we hereby submit the …
Annual reports
Concalls
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Jul 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Jun 2022Transcript PPT
Business Segments FY24[1]
Large Scale Manufacturing (59%) Advanced intermediates and specialty chemicals with application across the industry spectrum.
Contract Manufacturing (26%)
Manufacture under contractual supply agreements with MNCs.
CRAMS (14%)
Contract research, scale-up services, technology development, low volume high-value contract manufacturing.